Merger with Effimune to become a leader in immunotherapy
OSE Pharma announced its proposed merger with privately-held biotechnology company Effimune, which specializes in the development of treatments for auto-immune diseases and for cancer. The combined entity, to be named OSE Immunotherapeutics, will have a well-balanced pipeline of drug candidates whose mechanism of action relies on the activation and/or modulation of the immune system, giving the new company, a strong position in immunotherapy. The lead programs of OSE Immunotherapeutics, whose main strategy will remain immuno-oncology, would include OSE Pharma’s Tedopi currently in Phase III trial in Europe and the United States, for the treatment of NSCLC; and Effimune’s FR104, a drug candidate for Rheumatoid Arthritis. Janssen Pharmaceuticals (J&J group), is expected to exercise an option to license FR104 in H2-2016, to pursue the development of the drug in Phase II.
Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.